Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, PM

Similar documents
Urine Drug Testing Methods 3-5

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

Urine Opioid Dependency Panel (UODP) 1

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

Urine drug testing it s not always crystal clear

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?

Testing for Controlled Substances

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Welcome - SAMHSA s Role. Welcome SAMHSA Key Messages 4. Welcome SAMHSA s Direction

Pain Medication Management Program Supports Patient Outcomes and Adherence

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

Pain Medication Management Program Monitors Patient Compliance

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

Prescription Drug Monitoring Reference Guide: 2017

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Prescription Drug Abuse: Colorado and Nationwide

Toxicology 101. Arizona Problem Solving Courts April 25, 2016

Drug Screening. Separating Facts from Myths

Urine Drug Testing (UDT) in Pain Management. Nov 27, 2017

Urine Drug Testing (UDT) to Monitor Opioid Use. Feb 2018

Pharmacokinetics and Disposition of UDM Comparison of Various Sources for Drug Testing: Urine, Blood, Hair, Saliva. Edward J. Cone, Ph.D.

ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)

OTHER DRUGS OF ABUSE Source:

The Drug Testing Process. Employer or Practice

1. Amphetamine (Adderall, desoxyn, Dexedrine,dextrostat, spancap, oxydess II)

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

PARTICIPANT GENERAL INFORMATION

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Drug Adherence Assessment Report

WELCOME! 12/13/2018. Today s Topic: Urine Drug Screens in OUD Treatment UW PACC

Opioid Pain Contracts: A Resident Driven Quality Improvement Project

Toxicology Testing Is it a Good Fit for Your Laboratory? Rebecca Kenner, BA, MT, DLM(ASCP) Leigh Ann Smith, BS, MLS(ASCP), CLS

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

Opioid Use Disorder and Medication Assisted Recovery: Caring For Our Communities

nextgen precision Test Report

Laboratory Service Report

The Utility of Urine Drug Screening

Forensic Toxicology Scope of Testing and Detection Limits

Urine Drug Testing (UDT) in Pain Management. Nov 5, 2017

Patient Instructions

Urine Drug Screening: The Essentials of Interpretation

Mission. Maine Quality Counts is a member driven nonprofit located in Manchester, Maine.

Controlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

CNS DEPRESSANT OVERDOSE

URINE DRUG TOXICOLOGY

1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Interpretation of Pain Management Testing Results Using Case Examples

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

Treatment of the Addicted or Dependent Patient in the Family Practice Setting

Pinellas County Forensic Laboratory. Annual Report 2006

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Lesson 5 - Regulations and Standards Assignment Answer Key

Tests recently added to the NMS Labs test menu. New Tests are effective immediately.

Conflict of Interest Disclosure

Urine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

E XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS

European Guidelines for Workplace Drug Testing in UrineandOral fluid

Caring for ME, UNE and Portland s Public Health Department

How: or, Behind the Curtain.

PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH

3/8/2018. Reasons for Doing UDT. UDT: A Tool in Risk Assessment. Faculty/Presenter Disclosure. Urine Drug Testing in Chronic Pain Management

Applications of High Resolution Mass Spectrometry in Forensic Toxicology. Patrick Kyle, PhD.

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS

Lyndsey Knoy, D-ABFT-FT Forensic Scientist Washington State Toxicology Laboratory.

How many days does hydrocodone stay in your system

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

VIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY

CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)

Many companies conduct drug screenings. But you better avoid the following nine items and save yourself a world of frustration, if you need

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

Drug Screening: Things You Need to Know

Common Drugs of Abuse. What to look for, physical symptoms, and dangers

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

Learning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly

Schedule of Accreditation

INTERPATH LABORATORY, INC. TEST UPDATES

Evaluation of the Integrated E-Z Split Key Cup II for Rapid Detection of Twelve Drug Classes in Urine

One of These Tests is Not Like the Other: Comparative effectiveness, cost-effectiveness and utilization guidance in pain management testing

Xyrem (Sodium Oxybate)

Prescribing Opioid for. Opioid Naïve Patients AN OPIOD RX

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Transcription:

Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, 2018 12 1 PM Audio is available through your computer speakers.

Mission Maine Quality Counts is a nonprofit located in Manchester, Maine. We are working to improve the health of all Maine people (and beyond) by transforming the way healthcare is delivered.

Priorities QC Brings Together the People Who Give, Get and Pay for Healthcare to Address Shared Priorities: Improve the alignment of healthcare systems to transform health for all Maine people Provide quality improvement assistance to practices Engage consumers in healthcare Promote the integration of physical and behavioral health

Connect With Us Join our email list mainequalitycounts.org Engage and be social

Important Webinar Notes You are in listen-only mode. Please use the Q&A function to ask questions or make comments. Video screen size and location is adjustable. Tomorrow you ll receive an email with links to slides and recordings.

CME Disclosure: Today s speaker not have any relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME activity. CME will be available for participants who have signed into the live webinar. If there are multiple people at one computer, please type their names and email addresses into the chat box for our attendance records. We do not have separate nursing CEUs- but you can get a CME certificate. A CME evaluation survey will be will be sent after the webinar via email the day following the webinar. Please complete the survey via Survey Monkey within 2 weeks. NEW CME PROCESS: You will be able to immediately download your CME certificate on the last page of the survey. Please contact Jackie Tiner jtiner@mainequalitycounts.org if you have any questions, or problems downloading the document.

Funding Funding for this webinar is provided by: Board of Licensure in Maine

Objectives Provide an overview of the purposes of drug testing Describe mechanics behind screening and confirmatory drug testing Understand common sources for falsepositives and false-negative test results 8

Today s Speaker Jonathan Carl Fellers, MD Dr. Jonathan Fellers is an addiction psychiatrist in Portland, Maine and is affiliated with Maine Medical Center and Spring Harbor Hospital. He received his Bachelor of Science from the Massachusetts Institute of Technology and his medical degree from Cornell University Medical College. He completed his psychiatry residency at the University of Virginia where he served as Chief Resident. He completed a fellowship in Addiction Psychiatry at the Oregon Health and Science University and a postdoctoral fellowship at the MIRECC Portland VA Health Care System. Dr. Fellers joined MMC s Department of Psychiatry in September 2015 to head up the new Integrated Medication Assisted Therapy Team (IMAT). His work has expanded to include assisting MBH with the implementation of a treatment model across the MaineHealth footprint

Urine Drug Screening Maine Quality Counts November 20, 2018 Jonathan C Fellers, MD, FAPA Assistant Professor of Psychiatry, TUSM Medical Director, IMAT Program, MMC/MMP

Disclosures Nothing to disclose 11

Outline Why test? Specimen integrity Screening tests Confirmatory tests 12

13

14

15

16

17

Drug Testing Provides objective evidence of whether a drug was taken within a detection window - Prescribed medication adherence - Unreported substance use Serves a monitoring function that deters illicit drug use Enables clinical intervention for substance use disorders 18

Detection Window Drug Single Use Chronic Use Opiates 1 3 days 14 days (i.e. long-acting) Oxycodone 1 3 days Fentanyl < 1 day 3 days Alcohol < 12 hours 5 days (via EtG) Benzodiazepines 1 3 days 21 days (i.e. diazepam) Amphetamines < 3 days Cocaine < 4 days THC < 6 days 30 days Methadone 2 days 11 days

Specimen Integrity Addition of adulterants to interfere with test Diluting the specimen Substituting artificial urine Substituting one s own urine from a time when not using Substituting someone else s urine 20

Specimen Integrity Chain of custody - Chronological documentation showing the collection, transfer, receipt, analysis, storage, and disposal - Fully defensible and can disprove any allegations of tampering or misconduct Medical Review Officer (MRO) - Independent expert scrutiny of positive results - Prescribed medication exclusion 21

Specimen Integrity Tampering mitigation strategies - Removal of items from pockets - Remove unnecessary clothing or items - Secure water access (i.e. blue dye in toilet water) - Consider observation (i.e. listening, visual) 22

Specimen Integrity Quality assurance observation - Patient behavior (i.e. accident in bathroom) - Visual (i.e. color, clarity) - Odor (i.e. chemical or malodorous after storage) 23

Specimen Integrity Quality assurance testing - Temperature (i.e. 90 99º F) - ph (i.e. 4 10) - Specific gravity (i.e. 1.005 1.030) - Creatinine (i.e. 20 400) - Nitrates (i.e. none) - Oxidants (i.e. none) 24

Specimen Integrity 25

Screening Tests Usually the initial assay performed Advantages: - Ability to be performed at point-of-care (POC) - Rapid results - Low cost Disadvantages: - Lower sensitivity/specificity - Binary (positive/negative) results 26

Screening Tests Sensitivity - Immunoassays require a threshold amount of the target - Physiologic levels below this level and can lead to false negatives Specificity - May bind to unintended targets with a similar structure - Sometimes this is a moot point - In other cases, the poor specificity of immunoassays leads to false positives 27

Screening Tests Morphine Opiate Antibody Drugs that contain morphine: Morphine Opium Drugs metabolized to morphine: Codeine Heroin 28

Screening Tests 6-Monoacetyl Morphine Drugs metabolized to 6-Monoacetyl Morphine: Heroin Opiate Antibody 29

Screening Tests Oxycodone Drugs that contain oxycodone: Oxycontin Percocet Opiate Antibody 30

Screening Tests Fentanyl Drugs that contain fentanyl: Duragesic Spiked heroin Opiate Antibody 31

Screening Tests Test True Positive False Positive Amphetamine Amphetamine Bupropion, Ephedrine, Phentermine, Phenylephrine, Phenylpropanolamine, Promethazine, Pseudoephedrine Benzodiazepines Alprazolam, Clonazepam, Sertraline Diazepam, Lorazepam, Oxazepam, Temazepam, Triazolam Cocaine Benzoylecgonine Amoxicillin Methadone Methadone Diphenhydramine, Verapamil Opiates Oxycodone Heroin, Morphine, Codeine, Hydrocodone, Hydromorphone Oxycodone, Oxymorphone Dextromethorphan, Quinine, Quinolones, Rifampin THC THC Efavirenz, NSAIDs, PPIs 32

Confirmatory Tests Necessary to confirm a screening result Advantages: - Practically 100% sensitivity/specificity - Obtain levels - Can identify some drugs and metabolic products that screening tests cannot measure Disadvantages: - Expensive - Takes time to obtain results 33

Confirmatory Tests Sensitivity - Can detect targets at a much lower threshold than screening tests - e.g. fentanyl, clonazepam, ethyl glucuronide Specificity - Discriminates between structurally similar drugs - e.g. buprenorphine/norbuprenorphine, opiates, benzodiazepines, amphetamines 34

Alcohol and EtG Ethyl glucuronide (EtG) - Fairly specific for alcohol exposure - Can detect up to 5 days after exposure Ethyl sulfate (EtS) - Very specific for alcohol exposure Combination improves sensitivity and specificity Consumption of 30-33oz of beer (4.2 %) can result in EtG concentrations of 22,000-67,000 ng/ml at 3 hours

Opioid Metabolism Heroin 6-Monoacetyl Morphine Morphine Opium Codeine 36

Opiate Confirmatory Tests Heroin Opium Morphine (MS Contin) Codeine (Tylenol #3) Hydrocodone (Vicodin) Hydromorphone (Dilaudid) Oxycodone (Percocet, Oxycontin) Oxymorphone (Opana) Poppy seeds 6-Monoacetyl Morphine Morphine Codeine Hydrocodone Hydromorphone Oxycodone Oxymorphone 37

Benzodiazepine Metabolism Diazepam Temazepam Chlorazepate Nordiazepam Oxazepam Chlordiazepoxide 38

Benzodiazepine Confirmatory Tests Alprazolam (Xanax) Chlordiazepoxide (Librium) Clonazepam (Klonopin) Clorazepate (Tranxene) Diazepam (Valium) Flurazepam (Dalmane) Lorazepam (Ativan) Oxazepam (Serax) Temazepam (Restoril) Lorazepam Nordiazepam Oxazepam Temazepam Alpha-hydroxyalprazolam 7-aminoclonazepam Hydroxyethyl-flurazepam 39

Amphetamine Confirmatory Tests Amphetamine - Amphetamine illicit or prescribed (Adderall, dextroamphetamine) - As a metabolic product of another drug» Methamphetamine illicit or prescribed (Desoxyn, Vicks inhaler)» Benzphetamine, selegiline Methamphetamine - Methamphetamine illicit or prescribed (Desoxyn, Vicks inhaler) - As a metabolic product of another drug» Selegiline MDMA 40

Buprenorphine Confirmatory Tests Liver Buprenorphine Pattern of Behavior Consistent adherence Stopped, recently restarted Has not taken in a while Spiked sample with medication Not taking Norbuprenorphine Buprenorphine/Norbuprenorphine Norbuprenorphine > buprenorphine Buprenorphine > norbuprenorphine Norbuprenorphine only Buprenorphine only Neither present 41

42

43

44

45

46

Contact Information Amy Belisle, MD, MBA, Senior Medical Director abelisle@mainequalitycounts.org Kayla Cole, Project Manager kcole@mainequalitycounts.org Jackie Tiner, Administrative Coordinator jtiner@mainequalitycounts.org QC Website: https://mainequalitycounts.org/ 47

Upcoming Webinars! 1. Tuesday, November 27, 2018: 12:00 PM - 1:00 PM EST Registration MICIS: Opioid Use Disorder and Medication Assisted Recovery: Caring for Our Communities: Elisabeth Fowlie Mock 2. Tuesday, December 11, 2018: 12:00 PM - 1:00 PM EST Registration MICIS: Co-Prescribing Benzodiazepines and Opioids: The Black Box of Increased Overdose Risk: Elisabeth Fowlie Mock 3. Thursday, December 20, 2018 12:00 pm 1:00 PM MICIS; Alternative Treatments to Chronic Pain Registration Speaker: Elisabeth Fowlie Mock